How F-star are optimising bispecific antibodies for cancer treatment

Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?

July 10, 2019

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019

AACR18 Preview 5: is TGFβ an emerging cancer target?

A look at an emerging IO target that might be useful in ceratin tumour types and patient subsets when given in combination

April 4, 2018

Key trends in oncology R&D for 2018 – Part 1

New series on Key Trends in Oncology for 2018

January 4, 2018

A potential new IO combination for clinical development

People love hearing about new or emerging cancer targets - there's always the hope that one might find something cool that could move the needle and really make a difference...

December 8, 2017

IMpower150 lung cancer trial provides a window to the Future of Immunotherapy

The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?

December 7, 2017